In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with a price target of $17.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors, primarily focusing on Nuvectis Pharma’s lead asset, NXP900. The company has shifted its attention entirely to NXP900 following less favorable outcomes from another asset, NXP800. NXP900 is being developed to address a significant need in the treatment of non-small cell lung cancer, particularly for patients who have developed resistance to existing EGFR and ALK inhibitors. The upcoming Phase 1b study, which is set to begin shortly, is a critical step in advancing this promising therapy.
NXP900 has demonstrated potential in resensitizing cancer cells to antitumor treatments, which is a crucial development for patients with limited options. The study will include different patient cohorts, including those previously treated with EGFR and ALK inhibitors, to assess the drug’s efficacy in combination therapies. The financial position of Nuvectis, bolstered by recent funding, provides a runway into the second half of 2027, supporting the continued development of NXP900. These factors collectively underpin Rahman’s positive outlook and Buy rating for Nuvectis Pharma.
Rahman covers the Healthcare sector, focusing on stocks such as Nuvectis Pharma, Kazia Therapeutics, and Aytu BioScience. According to TipRanks, Rahman has an average return of -16.6% and a 30.94% success rate on recommended stocks.
In another report released on August 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.